Hangzhou Alltest Biotech Co.,Ltd. has a solid foundation with top-notch industry professionals, having proven expertise in innovation management including new introductions, be it a product or be it industry transforming process developments. We have been witness to as well as been part of core teams that have been responsible for transformations, which are critical to today's Rapid Tests as well as POCT business. Some of them include industry-leading design control systems that are responsible for innovative products with high quality as well as validations protocols that form the core of stringent quality assessment systems.
Hangzhou Alltest Biotech Co.,Ltd is the one by China NMPA, CE ISO13485, MDSAP international certification diagnostic company. Hangzhou Alltest Biotech Co.,Ltd. has been created with the sole objective of benefitting the stakeholders in the healthcare industry with major stake in POCT business including Rapid Tests, such as Women Health Rapid Test, Drug of Abuse Rapid Test, Infection Disease Rapid Test, Tumor Marker Rapid Test, Cardiac Marker and so on.
Hangzhou Alltest Biotech Co.,Ltd. is committed to bring Innovative Solutions including convergence of Rapid Tests' ease with the power of modern day electronics, thereby helping the creation of new technological platforms as well as business processes that unlocks the true potential of amalgamation of technology and commerce with new milestones in techno-commercial sectors of POCT industry.
|Earnings Per Share||16.82||1.94||1.43|
|R&D expenditure as a % of operating revenue||4.85%||14.89%||16.8%|
|Total Owners' Equity||972.66||293.2||215.1|
|Net Cash Flows-Operating||622.72||91.53||18.6|
|Net Cash Flows-Investing||-384.92||-40.39||-69.63|
|Net Cash Flows-Financing||-6.75||0||19.35|
|Name||No. of Shares Held (mn)||% of Shares Held|
|Hangzhou jingguan investment management co., ltd||12.50||23.18%|
|Hangzhou Qunze investment management co., ltd||10.15||18.83%|
|Shanghai Wenye Business Consulting Service Partnership Corporation (General Partnership)||1.89||3.51%|
|Hangzhou Saida Investment Partnership Corporation (Limited Partnership)||1.41||2.62%|
|Hangzhou Haibang Juqing Venture Capital Partnership Corporation (Limited Partnership)||1.05||1.95%|
|Hangzhou JinRui Investment Partnership Corporation (Limited Partnership)||1.05||1.95%|
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.